Thursday, August 10, 2006

Apotex Unleash Generic Plavix

Apotex in a surprised move is lastly launching generic Plavix, chemically known as clopidogrel bisulphate, in the US Plavix market which worth around US $ 3 billion. However, this move will put Apotex at risk because the patent infringement situation is still yet to be decided by the U.S. District Court for the Southern District of New York. Earlier, Sanofi and its US partner Bristol-Myer Squibb in March 2006 reached an out-of-court settlement with Apotex as result of which Apotex agreed not to sell a generic Plavix until 2011. Later, U.S. authorities rejected the deal in July, after which the Sanofi and Apotex has to restart their unsettled patent lawsuit.

1 comment: